Zolacabtagene autoleucel

佐拉卡基奥仑赛

Report date: 2026/05/25 20:02:40

Base Information

Drug NameZolacabtagene autoleucel
Drug Alias NameCC-97540BMS-986353NEX-T-CD19CD19-NEX-T
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > Autologous
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsScleroderma, SystemicLupus Erythematosus, SystemicPurpura, Thrombocytopenic, Idiopathic +[14] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[17] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesJuno Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesBristol Myers Squibb SrlcompanyUniversity of Texas Southwestern Medical CenterCelgene Corp +[4] 
Inactive CompaniesN/A
Active IndicationsScleroderma, SystemicLupus Erythematosus, SystemicPurpura, Thrombocytopenic, Idiopathic +[14] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A